Pipeline Programs↗
Active Trials↗
Companies Involved↗
Hemorrhage is a highly competitive landscape with 102 programs across 47 companies. 10 programs are in Phase 3.
Intelligence
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Pipeline
Analysis
93%
Small molecule
88 of 95 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 95 classified programs, each share of the total. Modality classified for 97% of 102 pipeline programs.
Analysis
443
clinical trials
Clinical Trials
443 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)